Also, PARP inhibitors, originally approved for HER2− metastatic BC in germline BRCA-1/2 mutation carriers, are now being investigated in patients with homologous recombination repair (HRR)-deficient BC, showing promising results [7,8,9]. The gene discussed is ERBB2; the disease is breast cancer.